Related references
Note: Only part of the references are listed.Evaluation of individual sensitivity of head and neck squamous cell carcinoma to cetuximab by short-term culture of tumor slices
Marine Peria et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2016)
Cytotoxicity and infiltration of human NK cells in in vivo-like tumor spheroids
Ariane Giannattasio et al.
BMC CANCER (2015)
Epidermal Growth Factor Receptor Inhibition Reduces Angiogenesis via Hypoxia-Inducible Factor-1α and Notch1 in Head Neck Squamous Cell Carcinoma
Wei-Ming Wang et al.
PLOS ONE (2015)
In Vivo Fluorescence Immunohistochemistry: Localization of Fluorescently Labeled Cetuximab in Squamous Cell Carcinomas
Esther de Boer et al.
SCIENTIFIC REPORTS (2015)
Increased sMICA and TGFβ1 levels in HNSCC patients impair NKG2D-dependent functionality of activated NK cells
Stephan Kloess et al.
ONCOIMMUNOLOGY (2015)
The hypoxic tumor microenvironment and drug resistance against EGFR inhibitors: preclinical study in cetuximab-sensitive head and neck squamous cell carcinoma cell lines
Carolien Boeckx et al.
BMC RESEARCH NOTES (2015)
Interleukin-2-stimulated natural killer cells are less susceptible to mycophenolate mofetil than non-activated NK cells: possible consequences for immunotherapy
Claudia Brehm et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Effect of tumor cells and tumor microenvironment on NK-cell function
Massimo Vitale et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2014)
Biomarkers of drugs targeting HER-family signalling in cancer
Filippo Montemurro et al.
JOURNAL OF PATHOLOGY (2014)
A Think Tank of TINK/TANKs: Tumor-Infiltrating/Tumor-Associated Natural Killer Cells in Tumor Progression and Angiogenesis
Antonino Bruno et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Genomic Analysis of Head and Neck Squamous Cell Carcinoma Cell Lines and Human Tumors: A Rational Approach to Preclinical Model Selection
Hua Li et al.
MOLECULAR CANCER RESEARCH (2014)
ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2014)
The ErbB/HER family of protein-tyrosine kinases and cancer
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2014)
Secretory pathways generating immunosuppressive NKG2D ligands New targets for therapeutic intervention
Aroa Baragano Raneros et al.
ONCOIMMUNOLOGY (2014)
Pre-emptive immunotherapy with purified natural killer cells after haploidentical SCT: a prospective phase II study in two centers
M. Stern et al.
BONE MARROW TRANSPLANTATION (2013)
Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma
Sofia Lyford-Pike et al.
CANCER RESEARCH (2013)
Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen-Specific T-cell Immunity in Head and Neck Cancer Patients
Raghvendra M. Srivastava et al.
CLINICAL CANCER RESEARCH (2013)
Immune alterations and immunotherapy prospects in head and neck cancer
Vincent Varilla et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2013)
The activity of γδ T cells against paediatric liver tumour cells and spheroids in cell culture
Alexander Hoh et al.
LIVER INTERNATIONAL (2013)
Clinical grade purification and expansion of NK cell products for an optimized manufacturing protocol
Ulrike Koehl et al.
FRONTIERS IN ONCOLOGY (2013)
IL-2-or IL-15-activated NK cells enhance Cetuximab-mediated activity against triple-negative breast cancer in xenografts and in breast cancer patients
Maria P. Roberti et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Histone deacetylase inhibitors impair NK cell viability and effector functions through inhibition of activation and receptor expression
Lucas E. Rossi et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2012)
Human Breast Tumor Cells Induce Self-Tolerance Mechanisms to Avoid NKG2D-Mediated and DNAM-Mediated NK Cell Recognition
Emilie Mamessier et al.
CANCER RESEARCH (2011)
Profound Coordinated Alterations of Intratumoral NK Cell Phenotype and Function in Lung Carcinoma
Sophia Platonova et al.
CANCER RESEARCH (2011)
Natural killer (NK):dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity
Steve C. Lee et al.
IMMUNOLOGIC RESEARCH (2011)
Activation of EGFR Promotes Squamous Carcinoma SCC10A Cell Migration and Invasion Via Inducing EMT-Like Phenotype Change and MMP-9-Mediated Degradation of E-Cadherin
Jian-Hong Zuo et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2011)
Phase II Study of Cetuximab in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small-Cell Lung Cancer: RTOG 0324
George R. Blumenschein et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
A Human NK Cell Activation/Inhibition Threshold Allows Small Changes in the Target Cell Surface Phenotype To Dramatically Alter Susceptibility to NK Cells
Tim D. Holmes et al.
JOURNAL OF IMMUNOLOGY (2011)
The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody
Don M. Benson et al.
BLOOD (2010)
Putative contribution of CD56 positive cells in cetuximab treatment efficacy in first-line metastatic colorectal cancer patients
Raphael Marechal et al.
BMC CANCER (2010)
The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors
Carol M. Lee et al.
BMC CANCER (2010)
Immune Suppression in Head and Neck Cancers: A Review
Anaelle Duray et al.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2010)
Immunotherapy of Malignant Disease with Tumor Antigen-Specific Monoclonal Antibodies
Michael Campoli et al.
CLINICAL CANCER RESEARCH (2010)
IL-2-activated haploidentical NK cells restore NKG2D-mediated NK-cell cytotoxicity in neuroblastoma patients by scavenging of plasma MICA
Stephan Kloess et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2010)
A novel anti-EGFR monoclonal antibody inhibiting tumor cell growth by recognizing different epitopes from cetuximab
Kwang-Won Hong et al.
JOURNAL OF BIOTECHNOLOGY (2010)
Tumor Antigen-Targeted, Monoclonal Antibody-Based Immunotherapy: Clinical Response, Cellular Immunity, and Immunoescape
Robert L. Ferris et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
IL-2-driven Regulation of NK Cell Receptors With Regard to the Distribution of CD16+ and CD16- Subpopulations and In Vivo Influence After Haploidentical NK Cell Infusion
Sabine Huenecke et al.
JOURNAL OF IMMUNOTHERAPY (2010)
TGF-beta downregulates the activating receptor NKG2D on NK cells and CD8(+) T cells glioma patients
Courtney A. Crane et al.
NEURO-ONCOLOGY (2010)
Detuning CD8+ T lymphocytes by down-regulation of the activating receptor NKG2D: role of NKG2D ligands released by activated T cells
Cristina Cerboni et al.
BLOOD (2009)
FcγRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck
Rodney J. Taylor et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells
Andres Lopez-Albaitero et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Cetuximab therapy for patients with advanced squamous cell carcinomas of the head and neck
William N. William et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2009)
Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56BrightCD16- cells and display an impaired capability to kill tumor cells
Paolo Carrega et al.
CANCER (2008)
Age-matched lymphocyte subpopulation reference values in childhood and adolescence: application of exponential regression analysis
Sabine Huenecke et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2008)
Tumor cell recognition by the NK cell activating receptor NKG2D
Yenan T. Bryceson et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2008)
Association between soluble MICA levels and disease stage IV oral squamous cell carcinoma in Japanese patients
Shigehiro Tamaki et al.
HUMAN IMMUNOLOGY (2008)
Human tumor-derived exosomes down-modulate NKG2D expression
Aled Clayton et al.
JOURNAL OF IMMUNOLOGY (2008)
The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor-positive tumor cells is enhanced by cytokines
Julie M. Roda et al.
CLINICAL CANCER RESEARCH (2007)
A novel five-colour flow cytometric assay to determine NK cell cytotoxicity against neuroblastoma and other adherent tumour cells
Stephan Kloeb et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2007)
Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines
Jun Kurai et al.
CLINICAL CANCER RESEARCH (2007)
Cytokine-driven regulation of NK cell functions in tumor immunity: Role of the MICA-NKG2D system
Norberto W. Zwirner et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2007)
The epidemiology and risk factors of head and neck cancer: a focus on human papillomavirus
C. C. R. Ragin et al.
JOURNAL OF DENTAL RESEARCH (2007)
Soluble MICB in malignant diseases: analysis of diagnostic significance and correlation with soluble MICA
Stefan Holdenrieder et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2006)
Soluble MIC is elevated in the serum of patients with pancreatic carcinoma diminishing γδ T cell cytotoxicity
Angela Maerten et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines
Heinz-Josef Lenz et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
The role of the NKG2D receptor for tumor immunity
Jerome D. Coudert et al.
SEMINARS IN CANCER BIOLOGY (2006)
Human natural killer cell development and biology
Sherif S. Farag et al.
BLOOD REVIEWS (2006)
Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL
Andres Lopez-Albaitero et al.
JOURNAL OF IMMUNOLOGY (2006)
Soluble MICA in malignant diseases
S Holdenrieder et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Inhibition of NK cell activity through TGF-β1 by down-regulation of NKG2D in a murine model of head and neck cancer
S Dasgupta et al.
JOURNAL OF IMMUNOLOGY (2005)
Natural-killer cells and dendritic cells: l' union fait la force
T Walzer et al.
BLOOD (2005)
Natural killer cell-dendritic cell crosstalk in the initiation of immune responses
T Walzer et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2005)
A novel four-colour flow cytometric assay to determine natural killer cell or T-cell-mediated cellular cytotoxicity against leukaemic cells in peripheral or bone marrow specimens containing greater than 20% of normal cells
SY Zimmermann et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2005)
Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia
HR Salih et al.
BLOOD (2003)
Global and regional estimates of cancer mortality and incidence by site: II. Results for the global burden of disease 2000
K Shibuya et al.
BMC CANCER (2002)
Expression of matrix metalloproteinase 1, matrix metalloproteinase 2, and matrix metalloproteinase 9 in carcinoma of the head and neck - Correlation with p53 status, inducible nitric oxide synthase activity, and anigogenesis
A Franchi et al.
CANCER (2002)
Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation
V Groh et al.
NATURE (2002)
Share Paper
